moxifloxacin has been researched along with Fever in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, X; Shi, M; Zhang, M | 1 |
| Shi, J; Si, X | 1 |
| Chen, F; Chen, Y; Fang, Q; Hu, S; Jiang, J; Liang, T; Lu, S; Sheng, J; Wei, N; Wu, L; Zheng, S; Zhou, J | 1 |
| Krogfelt, KA; Nielsen, HL; Prag, J | 1 |
| Jaeger, B; Pajkrt, D; Said, I; van de Beek, D; van Hest, RM; Wildenbeest, JG | 1 |
| Benjamin, RS; Frisbee-Hume, SE; Manzullo, EF; Patel, S; Rolston, KV | 1 |
| Adebambo, B; Senthilvel, E; Shah, C | 1 |
| Barker, EN; Chalker, VJ; Hamon, M; Jensen, J; Mitchell, J; Steer, JA; Stocki, T; Tasker, S | 1 |
| Hangaishi, A; Kurokawa, M; Masamoto, Y; Nannya, Y; Shinohara, A; Yoshiki, Y | 1 |
| Haeusler, GM; Slavin, MA | 1 |
| Slavin, MA; Thursky, KA | 1 |
| Akan, H; Akova, M; Aoun, M; Calandra, T; de Bock, R; Drgona, L; Kern, WV; Marchetti, O; Paesmans, M; Viscoli, C | 1 |
| Braun, J; Dirnagl, U; Halle, E; Megow, D; Meisel, A; Meisel, C; Prass, K; Victorov, I; Volk, HD; Wolf, T | 1 |
| Bamias, A; Chamilos, G; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostis, E; Papadimitriou, C; Zorzou, PM | 1 |
| Bachelot, T; Biron, P; Chelghoum, M; Chvetzoff, G; Devaux, Y; Dussart, S; Fuhrmann, C; Geoffrois, L; Ghesquieres, H; Lancry, L; Rodrigues, I; Sebban, C | 1 |
1 review(s) available for moxifloxacin and Fever
| Article | Year |
|---|---|
Neonate with Mycoplasma hominis meningoencephalitis given moxifloxacin.
Topics: Acyclovir; Amoxicillin; Anti-Bacterial Agents; Antiviral Agents; Cefotaxime; Cerebrospinal Fluid; Female; Fever; Fluoroquinolones; Humans; Infant, Newborn; Meningoencephalitis; Moxifloxacin; Mycoplasma hominis; Polymerase Chain Reaction | 2016 |
2 trial(s) available for moxifloxacin and Fever
| Article | Year |
|---|---|
Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectiou
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clavulanic Acid; Double-Blind Method; Drug Combinations; Female; Fever; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Neoplasms; Neutropenia; Quinolines; Risk Factors; Treatment Outcome | 2013 |
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Aza Compounds; Ceftriaxone; Female; Fever; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Neoplasms; Neutropenia; Patient Discharge; Quinolines; Risk Factors; Time Factors | 2008 |
12 other study(ies) available for moxifloxacin and Fever
| Article | Year |
|---|---|
Diagnosis and Analysis of Clinical Characteristics of
Topics: Amides; Animals; Anti-Bacterial Agents; Chlamydophila psittaci; Fever; Moxifloxacin; Nucleic Acids; Pneumonia; Psittacosis; Retrospective Studies | 2022 |
Pulmonary and Skeletal Infection of
Topics: Adult; Bone and Bones; Cough; Female; Fever; Follow-Up Studies; Humans; Levofloxacin; Lung; Magnetic Resonance Imaging; Moxifloxacin; Multimodal Imaging; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Positron-Emission Tomography; Rare Diseases; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.
Topics: Antibodies, Viral; Antipsychotic Agents; Antiviral Agents; Betacoronavirus; Bipolar Disorder; Brain; Chest Pain; China; Clinical Laboratory Techniques; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Testing; Darunavir; Dyspnea; Fever; Glucocorticoids; Humans; Indoles; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Olanzapine; Pandemics; Pharyngitis; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2 | 2020 |
Helicobacter cinaedi knee infection after arthroscopy in an immunocompetent patient.
Topics: Adult; Anti-Bacterial Agents; Arthroscopy; Fever; Fluoroquinolones; Helicobacter; Helicobacter Infections; Humans; Knee Injuries; Knee Joint; Male; Moxifloxacin; Rifampin; Species Specificity; Synovial Fluid; Treatment Outcome | 2015 |
Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Aza Compounds; Feasibility Studies; Female; Fever; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Neutropenia; Pilot Projects; Quinolines | 2010 |
Red eye, blurry vision, and cough.
Topics: Anti-Infective Agents; Aortic Valve; Aortic Valve Insufficiency; Aza Compounds; Blindness; Ceftriaxone; Cough; Echocardiography, Transesophageal; Endophthalmitis; Fever; Fluoroquinolones; Hearing Loss, Sensorineural; Heart Valve Prosthesis; Humans; Male; Middle Aged; Mitral Valve; Moxifloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae; Vancomycin; Vision Disorders | 2010 |
A novel hemotropic Mycoplasma (hemoplasma) in a patient with hemolytic anemia and pyrexia.
Topics: Anemia, Hemolytic; Anti-Bacterial Agents; Aza Compounds; Chronic Disease; Cluster Analysis; DNA, Bacterial; DNA, Ribosomal; Doxycycline; Female; Fever; Fluoroquinolones; Humans; Middle Aged; Molecular Sequence Data; Moxifloxacin; Mycoplasma; Mycoplasma Infections; Neutropenia; Phylogeny; Quinolines; RNA, Ribosomal, 16S; Sequence Analysis, DNA | 2011 |
Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents; Aza Compounds; Female; Fever; Fluoroquinolones; Hematologic Neoplasms; Humans; Male; Middle Aged; Moxifloxacin; Naphthyridines; Neutropenia; Quinolines; Retrospective Studies; Risk Factors; Treatment Outcome | 2013 |
Fluoroquinolone prophylaxis: worth the cost?
Topics: Antineoplastic Agents; Aza Compounds; Female; Fever; Fluoroquinolones; Hematologic Neoplasms; Humans; Male; Moxifloxacin; Naphthyridines; Neutropenia; Quinolines | 2013 |
Outpatient therapy for fever and neutropenia is safe but implementation is the key.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Female; Fever; Fluoroquinolones; Humans; Male; Moxifloxacin; Neoplasms; Neutropenia; Quinolines | 2013 |
Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke.
Topics: Animals; Antibiotic Prophylaxis; Aza Compounds; Bacterial Infections; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Escherichia coli Infections; Fever; Fluoroquinolones; Gram-Positive Bacterial Infections; Hypothermia; Immune Tolerance; Male; Mice; Mice, Inbred Strains; Moxifloxacin; Opportunistic Infections; Pneumonia, Bacterial; Quinolines; Sepsis; Stroke; Survival Rate; Treatment Outcome | 2004 |
Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Aza Compounds; Female; Fever; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Neoplasms; Neutropenia; Quinolines; Risk Assessment; Safety; Treatment Outcome | 2005 |